BACKGROUND: Repetitive transcranial magnetic stimulation (rTMS) has shown safety and efficacy for treatment-resistant depression, but requires daily treatment for 4-6 weeks. Accelerated TMS, with all treatments delivered over a few days, would have significant advantages in terms of access and patient acceptance. METHODS: Open-label accelerated TMS (aTMS), consisting of 15 rTMS sessions administered over 2 days, was tested in 14 depressed patients not responding to at least one antidepressant medication. Effects on depression, anxiety, and cognition were assessed the day following treatment, then after 3 and 6 weeks. RESULTS: No seizure activity was observed and only one patient had a serious adverse event (increased suicidal ideation). Two patients failed to complete a full course of aTMS treatments, and 36% did not complete all study visits. Depression and anxiety significantly decreased following aTMS treatments and improvements persisted 3 and 6 weeks later. Response rates immediately following treatment and at 3 and 6 weeks were 43, 36, and 36%, respectively. Remission rates at the same timepoints were 29, 36, and 29%. CONCLUSIONS: Accelerated TMS demonstrated an excellent safety profile with efficacy comparable to that achieved in daily rTMS in other trials. Limitations primarily include open-label treatment and a small sample size. Depression and Anxiety, 2010.
BACKGROUND: Repetitive transcranial magnetic stimulation (rTMS) has shown safety and efficacy for treatment-resistant depression, but requires daily treatment for 4-6 weeks. Accelerated TMS, with all treatments delivered over a few days, would have significant advantages in terms of access and patient acceptance. METHODS: Open-label accelerated TMS (aTMS), consisting of 15 rTMS sessions administered over 2 days, was tested in 14 depressedpatients not responding to at least one antidepressant medication. Effects on depression, anxiety, and cognition were assessed the day following treatment, then after 3 and 6 weeks. RESULTS: No seizure activity was observed and only one patient had a serious adverse event (increased suicidal ideation). Two patients failed to complete a full course of aTMS treatments, and 36% did not complete all study visits. Depression and anxiety significantly decreased following aTMS treatments and improvements persisted 3 and 6 weeks later. Response rates immediately following treatment and at 3 and 6 weeks were 43, 36, and 36%, respectively. Remission rates at the same timepoints were 29, 36, and 29%. CONCLUSIONS: Accelerated TMS demonstrated an excellent safety profile with efficacy comparable to that achieved in daily rTMS in other trials. Limitations primarily include open-label treatment and a small sample size. Depression and Anxiety, 2010.
Authors: David H Avery; Paul E Holtzheimer; Walid Fawaz; Joan Russo; John Neumaier; David L Dunner; David R Haynor; Keith H Claypoole; Chandra Wajdik; Peter Roy-Byrne Journal: Biol Psychiatry Date: 2005-09-01 Impact factor: 13.382
Authors: John P O'Reardon; H Brent Solvason; Philip G Janicak; Shirlene Sampson; Keith E Isenberg; Ziad Nahas; William M McDonald; David Avery; Paul B Fitzgerald; Colleen Loo; Mark A Demitrack; Mark S George; Harold A Sackeim Journal: Biol Psychiatry Date: 2007-06-14 Impact factor: 13.382
Authors: David H Avery; Keith E Isenberg; Shirlene M Sampson; Philip G Janicak; Sarah H Lisanby; Daniel F Maixner; Colleen Loo; Michael E Thase; Mark A Demitrack; Mark S George Journal: J Clin Psychiatry Date: 2008-03 Impact factor: 4.384
Authors: Sarah H Lisanby; Mustafa M Husain; Peter B Rosenquist; Daniel Maixner; Rosben Gutierrez; Andrew Krystal; William Gilmer; Lauren B Marangell; Scott Aaronson; Zafiris J Daskalakis; Randolph Canterbury; Elliott Richelson; Harold A Sackeim; Mark S George Journal: Neuropsychopharmacology Date: 2008-08-13 Impact factor: 7.853
Authors: Tyler S Kaster; Zafiris J Daskalakis; Yoshihiro Noda; Yuliya Knyahnytska; Jonathan Downar; Tarek K Rajji; Yechiel Levkovitz; Abraham Zangen; Meryl A Butters; Benoit H Mulsant; Daniel M Blumberger Journal: Neuropsychopharmacology Date: 2018-06-18 Impact factor: 7.853
Authors: A Irem Sonmez; Deniz Doruk Camsari; Aiswarya L Nandakumar; Jennifer L Vande Voort; Simon Kung; Charles P Lewis; Paul E Croarkin Journal: Psychiatry Res Date: 2018-12-07 Impact factor: 3.222